Volume 131, Issue 2, Pages 451-460 (August 2006) Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment  José M. Sánchez–Tapias, Moisés Diago, Pedro Escartín, Jaime Enríquez, Manuel Romero–Gómez, Rafael Bárcena, Javier Crespo, Raúl Andrade, Eva Martínez–Bauer, Ramón Pérez, Milagros Testillano, Ramón Planas, Ricard Solá, Manuel García–Bengoechea, Javier Garcia–Samaniego, Miguel Muñoz–Sánchez, Ricardo Moreno–Otero  Gastroenterology  Volume 131, Issue 2, Pages 451-460 (August 2006) DOI: 10.1053/j.gastro.2006.05.016 Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 1 Flow of participants throughout the study. Gastroenterology 2006 131, 451-460DOI: (10.1053/j.gastro.2006.05.016) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 2 Prediction of SVR by HCV-RNA decrease with respect to baseline at weeks 12 and 24 of treatment in patients from groups A and B. PPV, positive predictive value; NPV, negative predictive value. Gastroenterology 2006 131, 451-460DOI: (10.1053/j.gastro.2006.05.016) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions